Your browser doesn't support javascript.
loading
Stevens' Cure (Umckaloabo)-the vindication of a patent medicine.
Brendler, T; Stander, M A; van Wyk, B-E.
Afiliação
  • Brendler T; Department of Botany and Plant Biotechnology, University of Johannesburg, Johannesburg, South Africa.
  • Stander MA; Department of Biochemistry, University of Stellenbosch, Stellenbosch, South Africa.
  • van Wyk BE; Mass Spectrometry Unit, Central Analytical Facility, University of Stellenbosch, Stellenbosch, South Africa.
Front Pharmacol ; 14: 1294997, 2023.
Article em En | MEDLINE | ID: mdl-38235116
ABSTRACT
Stevens' Cure (Umckaloabo) emerged as a patent medicine claiming to treat tuberculosis in the United Kingdom at the beginning of the 20th century. However, due to its identity being shrouded in secrecy, it was never truly accepted by the medical community. It was "rediscovered" in the 1970s and subsequently developed into a very popular and successful phytopharmaceutical for the treatment of upper respiratory tract infections. Whether Stevens' Cure contained the same ingredient(s) as the modern Umckaloabo has not yet been demonstrated. We attempted to elucidate for the first time the identity of the original ingredient by comparative analysis of historical product samples. Three historical samples of Stevens' Cure were compared with Pelargonium sidoides DC. and P. reniforme Curt. root per UPLC-MS analysis. We confirm that the ingredient-P. sidoides DC.-is indeed the same as used in modern phytotherapy. We also attribute the first ethnopharmacological record of P. sidoides DC. being used for the treatment of tuberculosis to C. H. Stevens, the "creator" of Umckaloabo.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 3_ND Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Front Pharmacol Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 3_ND Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Front Pharmacol Ano de publicação: 2023 Tipo de documento: Article